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INTRODUCTION
Structure and synthesis 
Resveratrol (RSV) is a non-flavonoid polyphenol/phytoalexin, 
3,5,4’-trihydroxystilbene, a member of the viniferin family of 
polymers. It is a fat-soluble compound that exists in trans- and 
cis- configuration. The trans isomer is more active. It converts 
to cis form when exposed to UV irradiation. Both cis- and 
trans-RSV (Fig. 1) also occur as glucosides. The 3-β-glucoside 
of RSV is called piceid and is also biologically active (1). The 
synthesis of RSV from p-coumaroyl CoA and malonyl CoA 
in some plants is induced by stress, injury, fungal infection, 
or UV irradiation. The key enzyme is stilbene synthase (RSV 
synthase).
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Interest in the potential health benefits of resveratrol, a constituent of red wine, has increased significantly in the past decade. 
Extensive research has been done on it in attempt to reveal its clinical potential both in terms of disease prevention and treatment. 
Since initially resveratrol has been regarded as an explanation for the French paradox, attention of health professionals and 
journalists has been drawn to it. Called “promising molecule”, “star molecule” or “wonder drug”, resveratrol has been reposed 
hope as a cardioprotective, neuroprotective, anticancer, antiinflammatory, and antiaging molecule. Here we present state-of-the-
resveratrol elucidating its role in promotion of health and prevention of disease. Biomed Rev 2007; 18: 89-101.
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S t a t e - o f - t h e - m o l e c u l e s
“Quickly, bring me a beaker of wine, so that I may wet my mind and say something clever.” 
Aristophanes, ancient Greek comedy writer, 450-385 BC
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DISCOVERY AND ISOLATION
Now RSV is known as a compound of the grape skins and has 
been found in high concentration in red wines, but in 1963 in 
Japan Nonomura et al isolated it from the roots of the plant 
Polygonum cuspidatum (2). Japanese enjoyed for centuries the 
Itadori tea as a herbal remedy for heart disease and stroke (3). 
Nowadays the plant known as Japanese knotweed or Ko-jo-
kon in Japan and Huzhang in China, nevertheless considered 
an aggressive and noxious weed in Europe and America, is 
the most widely used and cheapest source of RSV for dietary 
supplements. 
 Resveratrol was isolated by Takaoka in 1939 from the roots 
of the white hellebore (Veratrum grandiflorum) (4). The name 
was most probably derived in the following way (5): res: might 
be an abbreviation of the class of molecules: RSV belongs to 
the resorcinols; veratr: abbreviation of the plant name, Ver-
atrum; ol: is generally used for indicating hydroxyl groups.  
In 1976 RSV has been characterized as phytoalexin, a sub-
stance synthesized by leaf tissue in response to fungal infection 
of grapevines (6). The fungus Botrytis cinerea (gray mold) 
induces RSV synthesis in healthy plants and the content of 
RSV in grapes determines the natural fungal resistance (7). 
This mechanism of defense has only been adopted by few plant 
species because most lack the key enzyme (8). The generally 
favorable biological responses to low exposure to stress are 
called (xeno)hormesis (see below).
 In 1992 Creasy (9) analyzed different red wines for their 
RSV content and identified trans-RSV as biologically active 
compound. He linked trans-RSV to the reduction of serum 
lipids and explained in this way some of the cardioprotective 
effects of red wine. 
SOURCES
Resveratrol is found in over 70 plant species including nuts, 
grapes, pine trees, certain vines and red wine (10). Generally, 
white wines contain 1–5% of the RSV content present in most 
red wines. Resveratrol’s most frequent plant sources are: root 
and rhizome of Polygonum cuspidatum (Fallopia Japonica); 
red grapes (skins, seeds, stalks, roots) of the Vitaceae fam-
ily vines, species Vitis vinifera (the European winemaking 
grapes), Vitis labrusca (the North American grapes) and Vitis 
rotundifolia, the muscadines (native grape grown of the south-
eastern USA), i.e. grape juice, must, pulp, pomace (the mass 
of grape skins, seeds and stems left after fermentation), wine; 
peanuts and pistachios; berries: blueberry, cranberry, mulberry, 
deerberry, bilberry, lingonberry, sparkleberry, partridgeberry, 
and jackfruit; trees: pines (Scots pine, eastern white pine), eu-
calyptus, spruce; flowers: white hellebore (veratrum); recently 
found in dark chocolate and cocoa (11).
 The amount of RSV in wines varies according to the cultivar, 
its geographic origin, its growing conditions, and exposure to 
triggers of its production. The amount of time a wine spends 
in contact with skins and pulp during fermentation is an 
important determinant of its RSV content. As white wines are 
not fermented on their skins, they have a very low amount of 
RSV, regardless some white grapes also produce it. Muscadine 
wines are more resistant to pests and diseases, including Phyl-
loxera, an insect that almost wiped out the European vineyards 
and devastated most of the European wine growing industry in 














(mg) in a 5 ounce 
(150 ml) glass 
Muscadine wines 14.1 – 40 2.12 – 6
Red wines 1.98 – 7.13 0.30 – 1.07
Red wines (Spanish) 1.92 – 12.59 0.29 – 1.89
Red grape juice 
(Spanish)
1.14 – 8.69 0.17 – 1.30
Rose wines 
(Spanish)
0.43 – 3.52 0.06 – 0.53
Pinot Noir 0.40 – 13.4 0.06 – 2.01
White wines 
(Spanish)
0.05 – 1.80 0.01 – 0.27
Table 1. Resveratrol content in wines and grape juice 
Figure 1. Structure of resveratrol.
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ABSORPTION AND BIOAVAILABILITY
Resveratrol has a good absorption of about 70% when given 
orally and intravenously, but has low bioavailability because 
it is rapidly metabolized and eliminated. The metabolites of 
RSV are resveratrol-3-sulphate, resveratrol-3-O-glucuronide 
and dihydroresveratrol. RSV has a plasma half-life of 9.2 ± 
0.6 h. After absorption only traces of the unchanged RSV are 
found in plasma (15). In another in vivo study trans-RSV were 
found only in some serum samples collected 30 min. after red 
wine ingestion while glucuronides predominated. Trans-RSV 
bioavailability was shown to be independent from the meal or 
its lipid content (16). The bioavailability of RSV from grape 
juice, which contains mostly RSV glucosides (piceid) may 
be even lower than that of trans-RSV, because the glicoside 
forms are absorbed to a lesser extent (17). 
ANTIOXIDANT ACTIVITY OF RESVERATROL
Resveratrol is an effective antioxidant in vitro. It scavenges 
reactive oxygen species (ROS) including oxygen ions, free 
radicals, and peroxides involved in oxidative stress (18-20). 
In some studies trans-RSV was found to be a better radical 
scavenger than vitamins E and C (18) but in others it was less 
potent than ascorbic acid (21). Resveratrol protects against and 
inhibits low-density lipoprotein (LDL) oxidation (22,23). 
 Resveratrol is a potent antioxidant in vivo. This property is 
probably a result of its ability to increase nitric oxide (NO) 
synthesis, which in turn functions as an in vivo antioxidant, 
scavenging superoxide radicals. Resveratrol (i) induces 
NO synthesis and lowers oxidative stress in the ischemic 
reperfused heart, brain, and kidney (24,25), (ii) manifests 
antioxidant activity in different cell culture lines, including 
cancer cell lines, (iii) inhibits proliferation that had been 
accompanied by a reduction in NO production or by an 
inhibition of inducible NO synthase (iNOS) (26,27), and (iv) 
maintains the concentrations of intracellular antioxidants like 
glutathione (GSH) (28) and increase the amounts of several 
antioxidant enzymes, including glutathione peroxidase, 
glutathione-S-transferase and glutathione reductase (29). 
The nuclear factor-kappa B (NF-k-B) signaling pathway can 
be evoked by oxidative stress and is inhibited by RSV (21). 
Tumor necrosis factor-alpha (TNF-α) -induced activation of 
NF-k-B is attenuated by RSV (30). RSV inhibits angiotensin-II 
(AT-II)-induced cardiomyocyte hypertrophy by inhibiting the 
AT-II-induced ROS production (31).
CARDIOPROTECTIVE ACTIVITY 
The French paradox, a very low mortality rate due to coronary 
heart disease (CHD) in France despite a high-saturated-fat diet 
and smoking habits (32), was first noted as a phenomenon by
the Irish physician Samuel Black in 1819, described in 1958 by 
British authors (33) and ascribed to red wine consumption inn 
1992 (34). Despite its validity has been questioned and other 
theories have been proposed to explain the paradox – under-
reporting or peculiarities of reporting CHD mortality in France, 
time lag explanation, pattern of drinking, the diet-heart hypoth-
esis etc. (35,36), the scientific interest in red wine remained
high. Numerous studies established that moderate alcohol 
consumption is beneficial and has a J-shaped mortality curve.
Clear proof for decreased total mortality associated with 2-4 
daily drinks for men and 1-2 for women versus abstinence or 
higher drinking rates came from a meta-analysis of mortality 
in 34 outcome studies on more than 1 million subjects with 
nearly 100 000 deaths analysed (37,38). Moderate wine 
drinkers had a 32% average decreased risk of cardiovascular 
disease compared to non-drinkers, and beer drinkers had less 
benefit. But is it alcohol, wine, red wine (39) or some red wine 
compounds? Resveratrol is one of wine constituents mostly 
believed to be responsible for this phenomenon. Whatever, 
"wine makes heart happy" (from Greek, oinos euphrainei 
cardian).
1 standard drink is 12 grams of alcohol, equivalent to 
one 12-ounce (360 ml) can or bottle of 4% beer or 6 oz 
(120 ml) of 8% beer, one 5-ounce (150 ml) glass of wine, 
or 1.5 ounces (45 ml) of 40% alcohol distilled spirits.
[1 fluid ounce = 30 ml]
Platelet aggregation
Resveratrol inhibits platelet aggregation in vitro and in 
vivo (40,41). This effect of RSV could be explained by its 
preferential inhibition of cyclooxygenase 1 (COX1) over 
COX2.  In this way the activity of prostacyclin, a vasodilaltor 
and antiplatelet aggregator, synthesized by COX1 in platelets, 
prevails over thromboxane A2, a potent vasoconstrictor 
and inducer of platelet aggregation, synthesized by COX2. 
Resveratrol may cause irreversible inactivation of COX1 under 
some conditions (42) thus having a lasting effect even after a 
short exposure in vivo.
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Vasorelaxation
Resveratrol exerts additional vasorelaxant effect on isolated 
porcine coronary arteries (43). As a possible mechanism for 
this was proposed its ability to stimulate Ca2+-activated K+ 
channels in endothelial cells (44) and to lead to decreased NO 
inactivation through inhibition of vascular NADH/NADPH 
oxidase activity (45). In vivo RSV leads to a coordinated 
upregulation of both iNOS and endothelial NO synthase 
(eNOS) (46,47), whereas failes to provide cardioprotection in 
iNOS knockout mice (48), but it reduces myocardial ischemia 
reperfusion injury through both iNOS-dependent and iNOS-
independent mechanisms (49). 
Anti-inflammatory effects�
The cardioprotective ability of RSV is also due to its anti- 
inflammatory effects in the ischemic heart. Possible mechanisms 
for its protective activities include the inhibition of synthesis 
and release of pro-inflammatory mediators, modifications of
eicosanoid synthesis, inhibition of activated immune cells, the 
enzymes COX1 and COX2, and transcription factors such as 
NFκB and activator protein-1 (AP-1) (50). Resveratrol inhibits 
the expression of adhesion molecules including intracellular 
adhesion molecule 1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1)  in cultured endothelial cells (51,52). 
Intravenously  administered RSV decreases inflammation 
induced by ischaemia/reperfusion in rats (53). Moderate 
hyperhomocysteinemia is an independent risk factor for 
cardiovascular disease and RSV has been found to suppress 
homocysteine formation in stimulated human peripheral blood 
mononuclear cells in vitro (54). 
Anti-apoptosis
Resveratrol is capable of inducing anti-apoptotic signaling, 
and thereby ensuring heart protection. In porcine coronary 
arteries, short term treatment with RSV significantly inhibited 
mitogen-activated protein kinase (MAPK) activities, and 
immunoblot analyses revealed consistent reduction in the 
phosphorylation of extracellular signal-regulated kinases 1/2 
(ERK1/2), Jun N-terminal kinase (JNK-1), and p38 MAPK 
(55). The same study found that RSV attenuated basal and 
endothelin 1-mediated protein tyrosine phosphorylation. 
Evidence for the anti-apoptotic function of RSV is further 
found in other studies, which have demonstrated a reduction 
of apoptotic cardiomyocytes in the ischemic reperfused heart 
that had been pretreated with RSV (48). Resveratrol, but also 
other wine compounds like proanthocyanidin, acts as a strong 
antioxidant and triggered a signal transduction cascade by 
reducing proapoptotic transcription factors and genes such 
as JNK-1 and c-Jun thereby potentiating an anti-death signal. 
This resulted in the reduction of myocardial infarct size and 
cardiomyocyte apoptosis in isolated rat hearts (56). However, 
RSV has been found to inhibit proliferation and to have a 
pro-apoptotic effect in different cancer cell lines (57, also 
see below).
Pharmacological preconditioning 
Preconditioning is the most powerful "technology" known 
to make the heart resistant to subsequent lethal ischemic 
injury. Most often preconditioning is performed by 4 cycles 
of ischemia (5 minutes each) followed by 10 minutes of 
reperfusion (58). The intracellular signaling mechanisms are 
second messenger pathways that involve components such 
as adenosine, adenosine receptors, NO, heat shock proteins 
(Hsp), protein kinase C, the mitochondrial ATP-dependent 
potassium channels, including a paradoxical protective role of 
oxygen free radicals (59). Recently it was determined that RSV 
may function as a pharmacological preconditioning agent. It 
improves postischemic ventricular functional recovery, reduces 
myocardial infarct size and also cardiomyocyte apoptosis. 
Additionally, RSV diminishes the amount of ROS activity, 
which was demonstrated through reduced malonaldehyde 
formation. Also, RSV exerts its preconditioning effect through 
NO (24). In normal tissue, RSV decreases the expression of 
iNOS, however in ischemic heart RSV induces iNOS. iNOS 
knockout mouse hearts could not be preconditioned with 
RSV in contrast to wild type mouse hearts (48). Resveratrol 
protects the ischemic heart through the increased expression 
of adenosine A1 and A3 receptors (60). 
Angiogenic properties 
Therapeutic angiogenesis is the clinical use of methods to 
enhance or promote the development of collateral blood vessels 
and thus improving blood flow to ischemic tissue. The neovas-
cularization is inducted by angiogenic agents administered as 
recombinant protein or by gene therapy. In the past decade the 
method has been applied in patients with coronary artery disease 
and peripheral artery disease. There are three major ways to 
promote angiogenesis: protein therapy (by vascular endothelial 
growth factor – VEGF, basic fibroblast growth factor - bFGF), 
gene therapy, and cell therapy (61). Three weeks after infarction, 
RSV treatment leads to increased expression of VEGF/Flk-1 
receptor (62) and eNOS and iNOS (46). 
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NEUROPROTECTIVE EFFECTS
The results of several studies indicate the usefulness of RSV 
in protecting against brain damage following focal or global 
cerebral ischaemia in rodents (63-65). Resveratrol is able to 
prevent seizures induced by kainic acid, FeCl3 or pentylene-
tetrazole (66-68). Chronic treatment with RSV counteracts in 
part streptozotocin-induced cognitive impairment (69). Recent 
data showed that RSV might also have a therapeutic poten-
tial in Alzheimer’s disease. Resveratrol markedly lowers the 
levels of secreted and intracellular amyloid-β (Abeta) peptides 
produced from different cell lines. It does not inhibit Abeta 
production, but promotes instead intracellular degradation 
of Abeta via a mechanism that involves the proteasome 
(70). Resveratrol is found to be neuroprotective in several 
models of Huntington’s disease (HD) - a nematode model 
and neuronal cell culture derived from a genetic HD mouse 
(HDhQ111 knock-in mice) (71), toxin mouse model of HD 
(72). Resveratrol appears to be beneficial in a mouse model
of amyotrophic lateral sclerosis (73). 
ANTICANCER EFFECTS 
In 1997 Jang et al reported that topical application of RSV 
has cancer chemopreventive activity in assays representing 
three major stages of carcinogenesis (74). Since then exten-
sive research on RSV’s anticancer activities has been done. 
In some studies RSV was efficient in low doses if adminis-
tered systemically (75) what suggests that it might possess 
therapeutic potential in concentration obtained from dietary 
sources, such as red wine. In other studies higher but phar-
macologically achievable doses have been used. RSV has the 
ability to suppress proliferation of a wide variety of tumor 
cells, including lymphoid and myeloid cancers; multiple 
myeloma; cancers of the breast, prostate, stomach, colon, 
pancreas, and thyroid; melanoma; head and neck squamous 
cell carcinoma; ovarian carcinoma; and cervical carcinoma 
(57). Numerous pre-clinical studies demonstrated the potential 
chemopreventive and chemotherapeutic activities of RSV 
on all three stages of carcinogenesis (initiation, promotion, 
and progression), in both chemically and UVB-induced skin 
carcinogenesis in mice, as well as in various murine models of 
human cancers (76). There are various mechanisms via which 
RSV exerts its anticancer effects (see below). 
Cell-cycle arrest and proapoptosis
Resveratrol induces cell cycle arrest in different cell phases 
by upregulation of p21Cip1/WAF1, p53, and Bax; down-
regulation of survivin, cyclin D1, cyclin E, Bcl-2, Bcl-xL, 
and cIAPs; and activation of caspases (57). Resveratrol has 
been shown to suppress the activation of several transcription 
factors, including NF-κB, AP-1, and Egr-1; to inhibit protein 
kinases including IκB·kinase, JNK, MAPK, Akt, PKC, PKD, 
and casein kinase II; and to down-regulate products of genes 
such as COX-2, 5-LOX, VEGF, IL-1, IL-6, IL-8, AR, and PSA. 
These activities account for the suppression of angiogenesis 
by this stilbene. Resveratrol has also been shown to potentiate 
the apoptotic effects of cytokines (e.g., TRAIL, tumor necrosis 
factor-related apoptosis-inducing ligand), chemotherapeutic 
agents and γ-radiation. Phamacokinetic studies revealed that 
the target organs of RSV are liver and kidney, where it is con-
centrated after absorption and is mainly converted to a sulfated 
form and a glucuronide conjugate. In vivo, RSV blocks the 
multistep process of carcinogenesis at various stages: it blocks 
carcinogen activation by inhibiting aryl hydrocarbon-induced 
CYP1A1 expression and activity, and suppresses tumor initia-
tion, promotion, and progression.
 Besides chemopreventive effects, RSV appears to exhibit 
therapeutic effects against cancer. Limited data in humans have 
revealed that RSV is pharmacologically quite safe. RSV acts 
as sensitizor of tumour cells to other inducers of apoptosis. 
RSV has no influence on normal human fibroblasts to TRAIL-
induced apoptosis, but it has been shown that it sensitizes 
several tumour lines (77).
Inhibition of cyclooxygenase and ornithine 
decarboxylase 
There is epidemiological evidence that long term COX inhibi-
tion may reduce the risk of developing of many cancers (78). 
In a mouse model of colorectal cancer, deletion of the gene 
encoding COX2 was shown to be protective (79). In vivo 
RSV reduces the total COX activity of tumours and normal 
tissue via moderately selective inhibition of COX1 activity 
and/or reduction of COX2 at the mRNA level. In vitro studies 
indicate that transcriptional inhibition of COX2, as well 
as ornithine decarboxylase (ODC), could be accomplished 
through inhibition of PKC (10). Resveratrol does not directly 
inhibit ODC activity (80), but reduces its expression in vivo 
and prevents its induction by carcinogens.
Inhibition of angiogenesis
In order to grow, tumors induce angiogenesis by secreting 
various growth factors like VEGF and are aided by enzymes 
called matrix metalloproteinases (MMP). RSV was shown to 
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inhibit tumor-induced neovascularization in vitro and ex vivo 
inhibiting the activities of MMP-2 (81) and the expression of 
MMP-9 (82). Both COX and ODC promote angiogenesis and 
their suppression by RSV could have an additional role.
EFFECTS ON DRUG METABOLISM
Resveratrol modulates the expression and activity of different 
drug-metabolizing enzymes suggesting that it could cause a 
reduction in the exposure of cells to carcinogens. Resveratrol 
and its metabolites inhibit the enzymatic activity of phase 1 en-
zymes - various cytochromes P450 (CYPs) in vitro: CYP2C19, 
CYP3A4; CYP3A, CYP1A, CYP2E1 (83,84). However this 
could interfere with the pharmacokinetics of other drugs. Other 
papers showed RSV’s capability of increasing the body’s 
capacity to eliminate harmful molecules by inducing phase II 
conjugating and antioxidant enzymes (85,86).
PHYTOESTROGENIC ACTIVITY 
On the basis of the structural similarity of RSV to the synthetic 
estrogen diethylstilbestrol it was hypothesized and proved that 
RSV is a phytoestrogen and thus an agonist for the estrogen 
receptor (ER) (87). Resveratrol was able to elicit a dose-
dependent activation of a luciferase reporter gene under the 
control of an estrogen response element (ERE) linked to the 
minimal thymidine kinase promoter in MCF-7 cells, an ER-
containing human adenocarcinoma breast cell line. In this cell 
line, RSV produces a greater maximal transcriptional response 
than ER, whereas in others it produces activation equal to or 
less than that of ER. Suboptimal doses of RSV and estrogen 
were additive. Upon binding ER, RSV activates transcription 
of estrogen-responsive reporter genes. However, other studies 
showed that RSV acts as a possible mixed agonist/antagonist, 
depending on the availability of specific ER isoform (88), 
possesses antiestrogen activity (89) or super- or anti-estrogenic 
activity, depending on the concentration (90). Most of the in 
vivo studies failed to reveal estrogenic potential of RSV ex-
cept a study on stroke-prone spontaneously hypertensive rats, 
demonstrating a decrease in the systolic blood pressure by 15% 
and stimulation of endothelium-dependent vascular relaxation 
in response to acetylcholine in ovariectomized rats (91).
RESVERATROL AND LONGEVITY  
Since the 1930s calorie restriction (CR) is known to extend 
the lifespan of a number of species, including mammals and 
nonhuman primates (92, 93). In the yeast Saccharomyces 
cerevisiae, CR extends lifespan by increasing the activity of 
Sir2 enzymes (94). In yeast, worms and flies, overexpression 
of the genes encoding sirtuins are reported to extend lifespan 
(95-96),  suggesting that sirtuins are evolutionarily conserved 
mediators of longevity, also called anti-senescent proteins. 
Sirtuins are a unique class of NAD(+)-dependent deacetylases, 
found in both prokaryotes and eukaryotes, and required for 
diverse biological processes. Sir2 is short for the gene Silent 
(mating type) Information Regulator-2 of Saccharomyces 
cerevisiae. Of the seven mammalian sirtuins (SIRT1–7), 
SIRT1 is the closest homologue to SIRT2. While RSV is now 
a well-recognized activator of sirtuins, nicotinamide is an 
inhibitor of their enzymatic activity. Note that valproic acid, 
a common drug for therapy of epilepsy and depression, is also 
a deacetylase inhibitor, that inhibits adiponectin production 
(97), an action that may contribute to metabolic side effect 
of this drug.
 Indeed, in the absence of CR, RSV has been found to be the 
most potent activator of SIRT1 out of 18 molecules after in 
vitro screening – it increased Sir2 activity in yeast and extended 
its replicative lifespan by 70% (98). By a similar mechanism 
RSV extended the lifespan of worms (C. elegans) and fruit flies
(D. melanogaster) (99) and was also found to increase dose-
dependently the lifespan of a vertebrate fish (N. furzeri) (100) 
and of mice on a high calorie diet, thus mimicking CR (101). 
Calorie restriction induces a shedding of body fat from white 
adipose tissue and an increase in insulin sensitivity. White 
adipose tissue appears to be a primary factor in longevity, 
as fat-specific insulin receptor knockout (FIRKO) mice live 
longer (102). At present, CR, though much promising in ani-
mal studies, doesn’t seem to be an attractive way for humans 
– for just a 6-month proof of its benefits only 48 participants
were found (103). Further searching for CR mimetics, includ-
ing RSV and its analogues, appears a novel alternative in 
the field. Adipogenesis is promoted by the nuclear receptor 
peroxisome proliferator-activated receptor-gamma (PPAR-γ). 
Thiazolidinedione antidiabetic drugs are agonist ligands for 
PPARγ and thus insulin sensitizors. RSV has also been shown 
to be a PPAR-γ ligand. Activating SIRT1, RSV attenuated 
adipogenesis by repressing PPAR-γ activity what lead to fat 
mobilization in white adipocytes and to triggering of lipolysis 
(104). Resveratrol may additionally modulate lifespan through 
inhibition of  insulin signaling pathway independently of 
SIRT1 activation by inhibiting insulin-induced MAPK and Akt 
(105). And last but not least, activating SIRT1, RSV increased 
the adiponectin levels in 3T3-L1 adipocytes (106). Reduced 
circulating levels of adiponectin usually accompany obesity, 
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diabetes, and atherosclerosis. All these data outline RSV as an 
important playmaker in cardiometabolic diseases and and with 
a possible role in achieving longevity. It is not known whether 
RSV can extend human lifespan. Clinical trials in humans are 
underway, one phase I study already completed (107), which 
will provide information on safety and efficacy of RSV given
in high doses as a dietary supplement.
 Resveratrol is a molecule with many targets (108) (Fig. 
2). The (xeno)hormesis hypothesis may in part explain such 
a pleiotropic potential of this wine-derived molecule (109). 
Calorie restriction, considered as mild stress, is a form of 
hormesis. Individuals (animals and possibly humans) that 
are mildly stressed, outlive their unstressed counterparts 
(10). Sirtuins evolved early in life’s history to increase 
somatic maintenance and survival during times of adversity. 
The hormesis hypothesis proposes that primordial species 
synthesized polyphenolic molecules to stimulate sirtuins 
during times of stress. Plants have retained this ability. 
Nevertheless animals and fungi have lost their ability to 
synthesize polyphenols, they have retained the ability to 
respond to plant stress signaling molecules. This ability 
would allow organisms to prepare for and survive adversity 
(109). If the xenohormesis hypothesis is correct, then stressed 
plants might form an abundant reservoir for medicinal 
compounds that trigger conserved protective responses in 
humans. There are numerous potential hormetics in a stressed 
plant that could act additively or even synergistically. An-
other potentially hormetic compound, quercetin (also a red 
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Figure 2. Molecular targets of resveratrol.
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CONCLUSION 
Resveratrol is a pluripotent molecule with numerous beneficial
effects, established in over 2000 studies (according Medline/
Pubmed information), thus making it the (present) king of red 
wine. Resveratrol is also a two-faced molecule, since it can 
protect healthy cells and selectively kill cancer cells; it behaves 
as an antioxidant, yet it can induce redox signaling; it induces 
apoptosis in tumor cells and blocks apoptosis in ischemic heart 
(59). Despite low bioavailability, low concentration of RSV is 
quite sufficient for the preconditioning of the heart. Red wine 
containing 1.2 mg/l of RSV can inhibit platelet aggregation by 
42%, even when it is diluted 100-fold (40). Preconditioning 
is the best method yet devised for cardioprotection, and 
RSV appears to fulfill the definition of a pharmaceutical 
preconditioning compound.
 But shall we trust the nature and enjoy 2-4 glasses of good red 
wine a day and/or reach out for RSV capsules or even powerful 
analogues? There is sufficient evidence that wine has protective
effect beyond alcohol, and that red wine is more useful than 
white wine regarding cardiometabolic biology (39). Among the 
reds remains the international debate, including Italy, France, 
Spain and soon Bulgaria to be involved, and the preference 
of Pinot Noir to Cabernet or Burgundy. Another important 
consideration is that beside RSV red wine contains other use-
ful compounds like flavan-3-ols (catechins, procyanidins), 
flavonols (quercetin) and anthocyanins (cyanidin, delphindin). 
The high content of red wine procyanidins may be essential 
to cardiovascular health (111). 
 One should be very cautious concerning transition of sci-
entific data into everyday life. There is no standing rule how
to estimate RSV daily dosage for humans from that given, 
for example, to a mouse. Is the sight of extended human 
lifespan real or it is only too much fuss because of commer-
cial interests in creating antiageing drugs? Behind the names 
of renown scientists show through the names of companies 
like Sirtris Pharmaceuticals (for Longevinex, RSV in pills, 
see www.longvinex.com) and Elixir Pharmaceuticals. Some 
other groups (112) could not reproduce the results of Sinclair 
et al, and even the ability of RSV to activate sirtuins has been 
questioned (113,114). Optimistically, sirtuins were included 
in the list of endogenous metabotrophic factors (115) and a 
recent study demonstrated that small molecules that are much 
more potent in activating sirtuins than RSV itself could exert 
anti-diabetic effect (116). Nevertheless, while the discussion 
is still hot and the probable role of sirtuin activators is still 
being elucidated let us rely on nature’s gifts and hope that a 
glass of red wine each day will keep cardiometabolic disease 
at bay.
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